Skip to main content

and
  1. Article

    Open Access

    Correction: Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease

    Pieter Jelle Visser, Lianne M. Reus, Johan Gobom in Molecular Neurodegeneration (2022)

  2. Article

    Open Access

    Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease

    Increased total tau (t-tau) in cerebrospinal fluid (CSF) is a key characteristic of Alzheimer’s disease (AD) and is considered to result from neurodegeneration. T-tau levels, however, can be increased in very ...

    Pieter Jelle Visser, Lianne M. Reus, Johan Gobom in Molecular Neurodegeneration (2022)

  3. Article

    Open Access

    APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer’s disease

    Aggregation of amyloid β into plaques in the brain is one of the earliest pathological events in Alzheimer’s disease (AD). The exact pathophysiology leading to dementia is still uncertain, but the apolipoprote...

    Elles Konijnenberg, Betty M. Tijms, Johan Gobom in Alzheimer's Research & Therapy (2020)

  4. No Access

    Article

    Biomarkers voor de ziekte van Alzheimer: relaties met vasculaire factoren, neurodegeneratie en cognitie in de predementiële fasen

    Hoewel biomarkers het inzicht in de ziekte van Alzheimer (AD) hebben vergroot, bestaat er nog veel onduidelijkheid en is er nog geen effectieve behandeling beschikbaar voor deze complexe aandoening. Vanuit de ...

    Isabelle Bos, Stephanie J. B. Vos, Frans R. J. Verhey, Pieter Jelle Visser in Neuropraxis (2019)

  5. Article

    Open Access

    MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study

    With the shift of research focus towards the pre-dementia stage of Alzheimer’s disease (AD), there is an urgent need for reliable, non-invasive biomarkers to predict amyloid pathology. The aim of this study wa...

    Mara ten Kate, Alberto Redolfi, Enrico Peira in Alzheimer's Research & Therapy (2018)

  6. Article

    Open Access

    The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics

    There is an urgent need for novel, noninvasive biomarkers to diagnose Alzheimer’s disease (AD) in the predementia stages and to predict the rate of decline. Therefore, we set up the European Medical Informatio...

    Isabelle Bos, Stephanie Vos, Rik Vandenberghe in Alzheimer's Research & Therapy (2018)

  7. Article

    Open Access

    Correction to: Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline

    Upon publication of this article [1], it was noticed that there were some inconsistencies in Tables 1, 2 and 3. Some of the superscript letters were incorrectly assigned. Please see below the correct tables:

    Isabelle Bos, Frans R. Verhey, Inez H. G. B. Ramakers in Alzheimer's Research & Therapy (2018)

  8. Article

    Open Access

    Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline

    Cerebrovascular disease (CVD) and amyloid-β (Aβ) often coexist, but their influence on neurodegeneration and cognition in predementia stages remains unclear. We investigated the association between CVD and Aβ ...

    Isabelle Bos, Frans R. Verhey, Inez H.G.B. Ramakers in Alzheimer's Research & Therapy (2017)